These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23335040)

  • 1. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.
    Ärnlöv J; Carlsson AC; Sundström J; Ingelsson E; Larsson A; Lind L; Larsson TE
    Clin J Am Soc Nephrol; 2013 May; 8(5):781-6. PubMed ID: 23335040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA; Wolf MS; Messinger S; Perwad F; Jüppner H; Warady BA; Furth SL; Salusky IB
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):1989-1998. PubMed ID: 27561289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome.
    Nakano C; Hamano T; Fujii N; Matsui I; Tomida K; Mikami S; Inoue K; Obi Y; Okada N; Tsubakihara Y; Isaka Y; Rakugi H
    Clin J Am Soc Nephrol; 2012 May; 7(5):810-9. PubMed ID: 22362065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM; Betoko A; Schneider MF; Salusky IB; Wolf MS; Jüppner H; Warady BA; Furth SL; Portale AA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):45-52. PubMed ID: 29025789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
    Westerberg PA; Tivesten Å; Karlsson MK; Mellström D; Orwoll E; Ohlsson C; Larsson TE; Linde T; Ljunggren Ö
    BMC Nephrol; 2013 Apr; 14():85. PubMed ID: 23587028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.
    Bushinsky DA; Spiegel DM; Yuan J; Warren S; Fogli J; Pergola PE
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):103-110. PubMed ID: 30381412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.
    Lundberg S; Qureshi AR; Olivecrona S; Gunnarsson I; Jacobson SH; Larsson TE
    Clin J Am Soc Nephrol; 2012 May; 7(5):727-34. PubMed ID: 22383747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R; Tan SJ; Hawley CM; Johnson DW; Stanton T; Lee K; Mudge DW; Campbell S; Elder GJ; Toussaint ND; Isbel NM
    BMC Nephrol; 2017 Sep; 18(1):281. PubMed ID: 28870151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-23 levels in patients with AKI and risk of adverse outcomes.
    Leaf DE; Wolf M; Waikar SS; Chase H; Christov M; Cremers S; Stern L
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1217-23. PubMed ID: 22700885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
    Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
    Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
    Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineral metabolites and CKD progression in African Americans.
    Scialla JJ; Astor BC; Isakova T; Xie H; Appel LJ; Wolf M
    J Am Soc Nephrol; 2013 Jan; 24(1):125-35. PubMed ID: 23243213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients.
    Chitalia N; Ismail T; Tooth L; Boa F; Hampson G; Goldsmith D; Kaski JC; Banerjee D
    PLoS One; 2014; 9(3):e91363. PubMed ID: 24646518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.